Jon Cuthbert

SunRice Group (ASX:SGLLV) has delivered a solid first-half performance for FY26, posting a 14% increase in net profit after tax to $36.6 million.

Terrain Minerals (ASX:TMX) announced a temporary pause in its 2025 reverse circulation drilling campaign at Smokebush Gold Project.

5E Advanced Materials (ASX:5EA) filed a foundational patent application with the US Patent and Trademark Office for its proprietary closed-loop in-situ leach boron mining and production process.

Boss Energy (ASX:BOE) has concluded its Honeymoon review and announced a new feasibility study.

Buru Energy (ASX:BRU) has provided an update on its 100% owned Rafael Gas Project.

Renegade Exploration (ASX:RNX) has signed a lease and option agreement granting it exclusive rights to explore and potentially acquire the Rooster Hill Monazite Project.

Bapcor (ASX:BAP) announced that Chris Wilesmith will succeed Angus McKay as CEO and Managing Director.

APA Group (ASX:APA) has announced the execution of a binding agreement to sell its 20% equity stake in GDI.

Traws Pharma (NASDAQ:TRAW) reported promising interim results from its Phase 2 trial of ratutrelvir, a ritonavir-free Mpro inhibitor, in the treatment of COVID-19.

The oral treatment, administered at a 600 mg once-daily dose for 10 days, was compared against PAXLOVID™ in a randomized, open-label study involving 37 patients—25 receiving ratutrelvir and 12 receiving PAXLOVID™.

NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.